PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.89%
Negative net income growth while AXSM stands at 18.58%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
6.88%
D&A growth well above AXSM's 3.41%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Negative yoy SBC while AXSM is 1.30%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-183.61%
Both reduce yoy usage, with AXSM at -170.25%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-219.11%
Both negative yoy AP, with AXSM at -61.41%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
200.00%
Some yoy usage while AXSM is negative at -149.24%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative yoy CFO while AXSM is 38.12%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
33.33%
We repay more while AXSM is negative at -67.20%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-53.76%
Both yoy lines negative, with AXSM at -26.32%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.